Literature DB >> 3191935

Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.

M Sano1, K Kawakatsu, C Ohkita, I Yamamoto, M Takeyama, H Yamashina, M Goto.   

Abstract

The effect of three new fluoroquinolones on theophylline kinetics and the urinary excretion of metabolites was studied in 5 healthy subjects (3 male, 2 female). All subjects received serial, single i.v. infusions of theophylline (aminophylline, 250 mg) over 60 min after 200 mg doses of a quinolone (enoxacin, ofloxacin, norfloxacin) every 8 h for 3 consecutive days, the quinolone being administered up to the day following theophylline administration. Pretreatment with ofloxacin and norfloxacin did not influence theophylline disposition, but theophylline clearance fell from 0.054 to 0.027 l.h-1.kg-1 in the presence of enoxacin, without a change in the apparent volume of distribution. Enoxacin, too, was the sole compound to increase the urinary excretion of theophylline (33.2 vs 43.9 mg, before vs after treatment), and significantly to decrease the excretion of 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) and 1,3-dimethyluric acid (1,3-DMU) in 24-h urine samples (from 19.8 to 7.16 mg, from 28.3 to 10.3 mg and from 68.8 to 49.5 mg, respectively). The effect of the quinolones on hepatic drug metabolizing enzyme activity was investigated in each subject using the ratios of 6-hydroxycortisol to total 17-hydroxycorticosteroids and to free cortisol in 24-h urines as an index of the hepatic P-450-dependent enzyme system. No significant difference in ratio was observed between control and other treatments. It is concluded that the theophylline-enoxacin interaction was largely due to inhibition of a metabolic system other than the common hepatic P-450 system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191935     DOI: 10.1007/bf00609246

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Decreased theophylline half-life in cigarette smokers.

Authors:  H Jenne; H Nagasawa; R McHugh; F MacDonald; E Wyse
Journal:  Life Sci       Date:  1975-07-15       Impact factor: 5.037

2.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

3.  Estimation of 17-hydroxycorticoids in urine.

Authors:  W J REDDY; D JENKINS; G W THORN
Journal:  Metabolism       Date:  1952-11       Impact factor: 8.694

4.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

5.  Pharmacokinetics of ofloxacin and theophylline alone and in combination.

Authors:  J B Fourtillan; J Granier; B Saint-Salvi; J Salmon; A Surjus; D Tremblay; M Vincent Du Laurier; S Beck
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  Quinolones and raised plasma concentrations of theophylline.

Authors:  F P Maesen; J P Teengs; C Baur; B I Davies
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

7.  Differential effects of cimetidine on theophylline metabolic pathways.

Authors:  J J Grygiel; J O Miners; R Drew; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

9.  Effect of age on patterns of theophylline metabolism.

Authors:  J J Grygiel; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

10.  The effect of 3-methylcholanthrene on urinary 6 beta-hydroxycortisol excretion and hepatic enzyme activity in the marmoset monkey (Callithrix jacchus).

Authors:  M Challiner; B K Park; J Odum; T C Orton
Journal:  Biochem Pharmacol       Date:  1981-08-01       Impact factor: 5.858

View more
  12 in total

1.  Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease.

Authors:  J Takahashi; K Kawakatsu; T Wakayama; H Sawaoka
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.

Authors:  M Sano; K Kawakatsu; I Yamamoto; M Takeyama; H Yamashina; M Goto
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.

Authors:  G Barnett; J Segura; R de la Torre; M Carbó
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.

Authors:  M Sarkar; R E Polk; P S Guzelian; C Hunt; H T Karnes
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

10.  Effect of fluconazole on theophylline disposition in humans.

Authors:  H Konishi; K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.